Serdar UĞRAŞ, Çetin ÇELİK, İsmail HARMANKAYA, Serra AKAR

Nicotinamide N-methyltransferase expression and its association with phospho-Akt, p53 expression, and survival in high-grade endometrial cancer

Background/aim: Nicotinamide N-methyltransferase (NNMT) is an enzyme that is overexpressed in malignancies. NNMT expressionhas not been previously studied in endometrial cancer (EC). Increased phospho-Akt (pAkt) levels in response to NNMT overexpressionhave been reported in in vitro studies of different cancer types. We assayed NNMT expression in primary and metastatic high-grade ECand investigated the relationship of NNMT with p53, pAkt, and survival.Materials and methods: NNMT, pAkt, and p53 expressions were assayed in 100 tissue samples of benign endometria, primary EC, andmetastatic EC by immunohistochemistry.Results: The NNMT immunoreactivity score was significantly higher in primary high-grade EC than benign endometrial tissue (P =0.001). NNMT expression in metastatic tissue was significantly higher than in primary cancer (P < 0.001). Metastatic stromal NNMTexpression was significantly higher than that of the adjacent tumor and stroma adjacent to the primary tumor. p53 expression inthe primary tumor showed a significant positive correlation with omental NNMT and pAkt expression. NNMT expression was alsocorrelated with pAkt expression in metastatic tissue. NNMT overexpression in metastatic tissue was associated with decreased survival(P = 0.039).Conclusion: This study suggests that NNMT may promote cancer progression and that NNMT overexpression is associated withaberrant p53 expression, pAkt, and poor survival. NNMT’s role in cancer progression could make it a target of EC therapy.

PDF

___

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer Journal for Clinicians 2016; 66: 7. doi: 10.3322/ caac.21551
2. Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M et al. Factors associated with type I and type II endometrial cancer. Cancer Causes & Control 2010; 21: 1851-1856. doi: 10.1007/ s10552-010-9612-8
3. Moore KN, Fader AN. Uterine papillary serous carcinoma. Clinical Obstetrics and Gynecology 2011; 54: 278-291. doi: 10.1097/GRF.0b013e318218c755
4. Sartini D, Seta R, Pozzi V, Morganti S, Rubini C et al. Role of nicotinamide N-methyltransferase in non-small cell lung cancer: in vitro effect of shRNA-mediated gene silencing on tumourigenicity. Biological Chemistry 2015; 396 (3): 225-234. doi: 10.1515/hsz-2014-0231
5. Palanichamy K, Kanji S, Gordon N, Thirumoorthy K, Jacob JR et al. NNMT silencing activates tumor suppressor PP2A, inactivates oncogenic STKs, and inhibits tumor forming ability. Clinical Cancer Research 2017; 23 (9): 2325-2334. doi: 10.1158/1078-0432.CCR-16-1323
6. Chen C, Wang X, Huang X, Yong H, Shen J et al. Nicotinamide N-methyltransferase: a potential biomarker for worse prognosis in gastric carcinoma. American Journal of Cancer Research 2016; 6 (3): 649-663.
7. Xu Y, Liu P, Zheng DH, Wu N, Zhu L et al. Expression profile and prognostic value of NNMT in patients with pancreatic cancer. Oncotarget 2016; 7 (15): 19975-19981. doi: 10.18632/ oncotarget.7891
8. Xie X, Liu H, Wang Y, Zhou Y, Yu H et al. Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. Oncotarget 2016; 7 (29): 45837-45848. doi: 10.18632/oncotarget.9962
9. Ulanovskaya OA, Zuhl AM, Cravatt BF. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nature Chemical Biology 2013; 9 (5): 300- 306. doi: 10.1038/nchembio.1204
10. Kanska J, Aspuria PP, Taylor-Harding B, Spurka L, Funari V et al. Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT. Oncotarget 2017; 8 (16): 26200-26220. doi: 10.18632/oncotarget.15429
11. Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM et al. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature 2019; 569 (7758): 723-728. doi: 10.1038/s41586-019-1173-8
12. Bach DH, Kim D, Bae SY, Kim WK, Hong JY et al. Targeting nicotinamide N-methyltransferase and miR-449a in EGFRTKI-resistant non-small-cell lung cancer cells. Molecular Therapy Nucleic Acids 2018; 11: 455-467. doi: 10.1016/j. omtn.2018.03.011
13. Kurman RJ, Carcangiu ML, Herrington CS, Young RH (editors). WHO Classification of Tumours. 4th ed. Lyon, France: IARC Press; 2014.
14. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. International Journal of Gynaecology and Obstetrics 2009; 105: 103.
15. Shepherd JH. Revised FIGO staging for gynaecological cancer. British Journal of Obstetrics and Gynaecology 1989; 96: 889-892.
16. Liang L, Zeng M, Pan H, Liu H, He Y. Nicotinamide N-methyltransferase promotes epithelial-mesenchymal transition in gastric cancer cells by activating transforming growth factor-β1 expression. Oncology Letters 2018; 15 (4): 4592- 4598. doi: 10.3892/ol.2018.7885
17. Campagna R, Cecati M, Pozzi V, Fumarola S, Pompei V et al. Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma. Cell Molecular Biology (Noisyle-grand) 2018; 64 (7): 51-55.
18. Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clinical Cancer Research 2015; 21 (15): 3561- 3568.
19. Tothill RW, Tinker AV, George J, Brown R, Fox SB et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical Cancer Research 2008; 14 (16): 5198-5208. doi: 10.1158/1078-0432.CCR-08-0196
20. Nilsson E, Doraiswamy V, Parrott JA, Skinner MK. Expression and action of transforming growth factor beta (TGFβ1, TGFβ2, TGFβ3) in normal bovine ovarian surface epithelium and implications for human ovarian cancer. Molecular Cellular Endocrinology 2001; 182: 145-155.
21. Wang X, Sun X, Mu L, Chen W. Cancer-associated fibroblasts induce epithelial-mesenchymal transition in endometrial cancer cells by regulating pituitary tumor transforming gene. Cancer Investigation 2019; 37: 134-143. doi: 10.1080/07357907.2019.1575969
22. Kim J, Hong SJ, Lim EK, Yu YS, Kim SW et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. Journal of Experimental & Clinical Cancer Research 2009; 28: 20. doi: 10.1186/1756-9966- 28-2.
23. Pozzi V, Sartini D, Rocchetti R, Santarelli A, Rubini C et al. Identification and characterization of cancer stem cells from head and neck squamous cell carcinoma cell lines. Cellular Physiology & Biochemistry 2015; 36 (2): 784-798. doi: 10.1159/000430138
24. Liu X, Fan D. The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links. Current Pharmaceutical Design 2015; 21 (10): 1279-1291. doi: 10.2174/13 81612821666141211115611
25. Jung J, Kim LJY, Wang X, Wu Q, Sanvoranart T et al. Nicotinamide metabolism regulates glioblastoma stem cell maintenance. Journal of Clinical Investigation Insight 2017; 2 (10): 90019. doi: 10.1172/jci.insight.90019
26. Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M et al. Gainof-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 2015; 525 (7568): 206-211. doi: 10.1038/ nature15251